America’s reliance on Chinese-made pharmaceuticals highlighted in bombshell report

President Donald Trump recently disturbed the customs duties on pharmaceutical imports, and his administration began to increase investigations into the case this week.

The administration said that these definitions are necessary to restore pharmaceutical manufacturing to the United States, which was classified as the issue of national security. This comes at a time when the AI ​​Exiger supply chain company appears to be based on Chinese Chinese drugs.

In the Exiger report, “Bitter Birthday Pills: The dangerous dependence in America on Chinese Chinese drugs”, the company explains that American patients are at risk of obtaining low-quality drugs-or nothing at all-under the current system.

President Donald Trump said he would target the drug industry with definitions. (Getty Images / Getty Images)

The Trump official is moving towards the semi -Mosul

“We were very concerned about the fact that after the epidemic, the strategic national storage efforts and the type of restoration, as you know, the independence of the United States when it comes to medicines and medical devices has lost a kind of back wind,” said Brandon Daniels, Executive CEO of Fox Business. He also said that the elderly and those who rely on critical general medications are most at risk of suffering from problems in the current pharmaceutical import system.

According to Exiger, the United States is currently importing 75 % of its basic drugs, most of which come from China and India. While India produces about half of the general drugs imported by the United States, it depends greatly on China for 80 % of its active pharmaceutical components (APIS). More than 500 general drugs depend on applications in one country, including diabetes treatments, heart disease as well as antibiotics.

Another factor that endangers Americans is the use of forced work in drug production. Exiger found that many suppliers, including Sinopharm, Zhejiang Shindai Chemical Group and Zhejiang Chemicals Corp. They relied on forced work in Ouigor, Xinjiang. The Customs and Borders patrol is supposed to prevent goods made from forced work; However, some still pass.

In the Exiger report, the company explains that American patients are at risk of obtaining low -quality drugs or nothing at all under the current system. (Istock / Istock)

White House trading head says Trump has no plans to speak with Shi Jinping about the war of tariffs

Daniels spoke with Fox Business about the risks of involving forced work in the pharmaceutical industry, including ethics and quality of products.

“Many of these sites that have been found are linked to forced work, they have people who literally wander without shoes in dirty facilities, facilities and facilities that do not draw and fit with the good manufacturing process standards that all our medications should meet,” Daniels told Fox Business:

Exigr’s CEO also indicated an incident in which drug shipments containing hydrogen cyanide are.

In the 2023 incident, the sponsorship of the Indian -based samples of KILTCHCACACACAN, which is based in India -based, has led to visual loss and permanent infections in some patients. The contaminated ingredients produced by Kiltch Healthcare have been used in a variety of brand products, according to the Exiger report.

In its report, EXIger recommends creating a strategic national stock of medicines, vaccines and basic devices. In addition, the United States urges the diversification of its supply chains, eliminating forced labor, enhancing the supervision of the FDA and enhancing local public drug production.

The Trump administration said that these definitions are necessary for pharmaceutical re -manufacturing to the United States (Geoffrey Greenberg Group / Universal Pictures via Getty Images / Getty Images)

Get Fox Business while clicking on click here

“I think there is a way for more manufacturing in the United States specifically, when it comes to biotechnology,” Daniels told Fox Business. “We are still power in terms of intellectual property of biotechnology, but I don’t think this will be the only answer.”

The Ministry of Commerce launched an investigation on the effects of national security security on April 1, according to the Federal Register. The administration said that it is looking for public and non -genetic drug products, medical measures, applications facades and other important components of these imports.